Summary

mRNA Synthesis and Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product (Drug Substances (APIs) and Drug Products (FDFs)), Application Area (mRNA-based Vaccines and mRNA-based Therapeutics), Therapeutic Area (Infectious Diseases, Oncological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)
Report Link: https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market.html
The cell and gene therapy CRO market is expected to reach 1.06 billion in 2024 anticipated to grow at a CAGR of XX% during the forecast period 2024-2035.

Ribonucleic acid (RNA) is a pervasive molecule present in all living cells, tasked with the crucial role of converting genetic instructions into proteins essential for numerous cellular functions. It exists in various forms, such as messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). Among these, mRNA has gained significant traction in contemporary healthcare as a pivotal therapeutic avenue. Acting as a single-stranded carrier, mRNA conveys genetic data from DNA to orchestrate protein synthesis. This genetic information encoded on mRNA undergoes translation into amino acids, ultimately culminating in the production of functional proteins.

The emergence of mRNA-based vaccines and therapeutics has garnered substantial attention since the onset of the COVID-19 pandemic. These innovations not only address COVID-19 but also hold promise for treating diverse conditions like cancer, infectious diseases, and genetic disorders. Yet, the production of mRNA therapies and vaccines is intricate and costly, requiring specialized knowledge and resources. Consequently, developers in this field are actively seeking solutions to surmount these obstacles. Outsourcing has surfaced as an appealing avenue for mRNA developers, offering potential resolutions to these complexities. Further, the landscape suggests robust growth in the mRNA synthesis and manufacturing market. Factors contributing to this growth include the rising incidence of chronic ailments, escalating demand for gene therapy, the evolution of RNA-based treatments through clinical and commercial phases, and advancements in technology.



Research Coverage:
This module presents overview of the structural and historical development of mRNA vaccines, offering insights into their evolution over time. It comprehensively discusses synthetic mRNA production, encompassing both chemical and in vitro methods, and explores their applications across diverse therapeutic domains. Additionally, it outlines the challenges inherent in mRNA synthesis and manufacturing processes. Moreover, the module explores commonly outsourced manufacturing operations related to mRNA and highlights their advantages.
The chapter offers a thorough assessment of mRNA custom synthesis service providers, taking into account various pertinent parameters, such as year of establishment, company size (measured by employee count), headquarters location (spanning North America, Europe, and the Asia Pacific region), types of services provided (such as mRNA modification, purification, scale-up, process development, and fill/finish), starting materials utilized (including plasmid DNA, mRNA sequence, PCR fragments), structural modifications undertaken (covering 5’ and 3’ modifications, ribonucleotide base modifications, among others), purification methodologies employed (ranging from chromatography to electrophoresis to desalting/precipitation), application areas served (including vaccine and therapeutic production, among others), and operational scale (encompassing preclinical/research, clinical, and commercial stages). Furthermore, this chapter presents details on the length of mRNA manufactured and the production capacity of the stakeholders.
The module conducts a thorough competitiveness analysis of mRNA custom synthesis service providers across significant geographical regions. This assessment considers both supplier and service strengths, evaluating factors such as years of experience and company size to gauge supplier strength. Additionally, service strength is scrutinized, encompassing the range and diversity of services provided, types of modifications offered, operational scale, adherence to Good Manufacturing Practices (GMP), and the breadth of application areas served.
This module conducts a comprehensive evaluation of mRNA contract manufacturing service providers, taking into consideration several key parameters, including the year of establishment, company size, location of headquarters, and the location of manufacturing facilities. Furthermore, the assessment includes an analysis of the types of additional services offered, such as formulation development, analytical testing, process development, mRNA purification, fill/finish operations, scale-up capabilities, and regulatory support services. It also delineates the type of products manufactured, distinguishing between active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), and considers the scale of operation across preclinical / research, clinical, and commercial stages.
This module conducts an extensive company competitiveness analysis of mRNA contract manufacturing service providers across key geographical regions, with a focus on evaluating both supplier and service portfolio strengths. Supplier strength was evaluated based on the year of experience and company size, providing insight into the stability and maturity of the provider. Meanwhile, service portfolio strength encompasses a multifaceted assessment, considering factors such as the number of facilities, the diversity of products manufactured, the breadth of services offered, and the scale of operations. This comprehensive evaluation offers understanding of each provider's competitive position in the mRNA contract manufacturing landscape.
This chapter presents a comprehensive evaluation of the current market landscape of mRNA synthesis kits, considering various parameters, such as components of kits (enzyme mix, reagents, buffers), the types of enzymes utilized (capping enzyme and tailing enzyme), variants of enzyme mixes (T7 polymerase, SP6 polymerase, and T3 polymerase), mRNA components modified (cap, base, and tail), the number of reactions per kit (5 to 50 reactions), yield per reaction (microgram ranges), the duration of reaction run time, and the price of the kit. Furthermore, this chapter provides an extensive analysis of mRNA synthesis kit providers, offering insights into their year of establishment, company size, location of headquarters, and identifies the most active players in terms of the number of mRNA synthesis kits offered.
The analysis delves into mRNA synthesis kits, with a dual focus on supplier strength and product attributes. Supplier strength takes into consideration the years of experience and company size, offering insights into reliability and industry tenure. On the other hand, product strength is evaluated based on key attributes, including the number of kit components, types of enzymes included (capping and tailing enzymes), modifications to mRNA components (cap, base, tail), yield per reaction, number of reactions per kit, reaction run time, and kit price. This comprehensive assessment provides understanding of both the providers and the characteristics of their mRNA synthesis kits, aiding in informed decision-making for consumers.
The module presents detailed company profiles of top mRNA manufacturing companies, highlighting their robust service offerings. Each profile comprises a company overview, covering year of establishment, location of headquarters, employee count, and leadership team. Furthermore, it delves into mRNA synthesis and manufacturing services, highlighting recent advancements and offering informed perspectives on future developments. This comprehensive overview offers valuable insights into the key players shaping the landscape of mRNA manufacturing, aiding stakeholders in making informed decisions.
Comprehensive profiles of leading mRNA synthesis kit providers renowned for their robust product portfolios. Each profile presents a concise company overview, accompanied by the details pertaining to their mRNA synthesis kit offerings.
Exhaustive analysis of partnerships signed within the industry between 2019 and 2023, considering a range of parameters, such as year of partnership, the type of partnership, type of product, type of partner, and most active players based on the quantity of partnerships signed. Furthermore, it provides insights into the regional distribution of the companies engaged in these collaborations, shedding light on the geographic trends and concentrations of partnership activities within the industry.
This analysis presents a thorough examination of over 35 developers specializing in mRNA-based therapeutics and vaccines, selected as potential partners for mRNA contract manufacturing service providers. These developers have been meticulously shortlisted based on a range of parameters, including the strength of the developer (assessed by company experience), company size (measured by the number of employees), pipeline robustness (evaluated by the quantity of mRNA-based drugs in the pipeline), highest development phase attained, therapeutic focus, route of administration, and the type of candidates under development. This comprehensive approach ensures the identification of suitable partners for collaboration within the mRNA-based therapeutics and vaccines landscape.
The analysis conducts a comprehensive examination of various mRNA-focused initiatives undertaken by major pharmaceutical companies, chosen based on their 2023 revenues. This review elucidates trends across multiple parameters, encompassing the quantity of initiatives, initiation year, purpose, type, and therapeutic focus of each initiative. By scrutinizing these diverse initiatives, this examination provides valuable insights into the strategic directions and priorities of leading pharmaceutical companies in the realm of mRNA-based research and development.
The analysis conducts a detailed examination of the factors influencing the growth of the mRNA synthesis and manufacturing market. This comprehensive study entails the identification and scrutiny of key drivers propelling market expansion, potential restraints hindering growth, emerging opportunities for market advancement, and existing challenges that may impede progress. By meticulously assessing these factors, the analysis offers valuable insights into the dynamics shaping the trajectory of the mRNA synthesis and manufacturing market.
In-depth forecast analysis of the mRNA synthesis and manufacturing market to estimate both the current market size and the future opportunities up to the year 2035. Utilizing multiple parameters such as anticipated adoption trends and rigorous primary validations, we have derived an informed estimate of the market evolution during the forecast period from 2024 to 2035. Furthermore, this module outlines the likely distribution of the current and forecasted opportunities within the mRNA synthesis and manufacturing market. To enhance the robustness of our model and to accommodate future uncertainties, we have developed three forecast scenarios: conservative, base, and optimistic. These scenarios represent different trajectories of industry growth, providing a comprehensive perspective on potential market developments.
Detailed projections have been formulated for the current and future mRNA synthesis and manufacturing market, categorized by type of product, encompassing both drug substances and drug products. These projections offer comprehensive insights into the anticipated growth trajectories, market sizes, and emerging trends for each product type within the mRNA synthesis and manufacturing landscape.
Detailed projections of the current and future mRNA synthesis and manufacturing market across application area, such as mRNA-based vaccines and mRNA-based therapeutics.
Detailed projections of the current and future mRNA synthesis and mRNA manufacturing market across therapeutic area, such as infectious diseases, oncological disorders and other disorders.
Detailed projections of the current and future mRNA synthesis and manufacturing market across key geographies, such as North America, Europe, Asia-Pacific, and Rest of the World.
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the mRNA Synthesis and Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
Aldevron
APExBIO
Aurigene Pharmaceutical Services
Biomay
CELLSCRIPT
Curia
eTheRNA
Enzynomics
Eurogentec
Genscript
Jena Bioscience
Merck KGaA
New England Biolabs
Vernal Biosciences
ST Pharm
Thermo Fisher Scientific
TriLink BioTechnologies
WuXi Biologics

ページTOPに戻る

Table of Contents

1. PREFACE
1.1. mRNA Synthesis and mRNA Manufacturing Market
1.2. Market Share Insights
1.2.1. Market Segmentation Overview
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations

2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Overview of mRNA
5.2. Structure of mRNA
5.3. Evolution of mRNA Vaccines
5.4. Steps involved in mRNA Synthesis
5.4.1. Chemical Synthesis of mRNA
5.4.2. In vitro Synthesis of mRNA
5.5. Applications of Chemical/ in vitro Synthesized mRNA
5.6. Challenges Associated with mRNA Synthesis

5.7. mRNA Contract Manufacturing
5.7.1. Commonly Outsourced mRNA Manufacturing Operations
5.7.2. Advantages of Outsourcing Manufacturing Operations

6. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: MARKET LANDSCAPE
6.1. mRNA Custom Synthesis Service Providers: Market Landscape
6.1.1. Analysis by Year of Establishment
6.1.2. Analysis by Company Size
6.1.3. Analysis by Location of Headquarters
6.1.4. Analysis by Type of Service Offered
6.1.5. Analysis by Starting Material
6.1.6. Analysis by Structural Modification
6.1.7. Analysis by Type of Purification Method
6.1.8. Analysis by Application Area
6.1.9. Analysis by Scale of Operation
6.1.10. mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Synthesized
6.1.11. mRNA Custom Synthesis Service Providers: Information on mRNA Production Capacity

7. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Methodology
7.3. Scoring Criteria

7.4. mRNA Custom Synthesis Service Providers: Company Competitiveness Analysis
7.4.1. mRNA Custom Synthesis Service Providers based in North America
7.4.2. mRNA Custom Synthesis Service Providers based in Europe
7.4.3. mRNA Custom Synthesis Service Providers based in Asia-Pacific

8. COMPANY PROFILES: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS
8.1. Chapter Overview
8.2. Detailed Company Profiles of Leading Service Providers
8.2.1. Aldevron
8.2.1.1. Company Overview
8.2.1.2. mRNA Custom Synthesis Service Portfolio
8.2.1.3. Recent Developments and Future Outlook

8.2.2. TriLink BioTechnologies
8.2.2.1. Company Overview
8.2.2.2. mRNA Custom Synthesis Service Portfolio
8.2.2.3. Recent Developments and Future Outlook

8.2.3. eTheRNA
8.2.3.1. Company Overview
8.2.3.2. mRNA Custom Synthesis Service Portfolio
8.2.3.3. Recent Developments and Future Outlook

8.3. Short Profiles of Other Prominent Custom Service Providers
8.3.1. Biomay
8.3.1.1. Company Overview
8.3.1.2. mRNA Custom Synthesis Service Portfolio

8.3.2. Genscript
8.3.2.1. Company Overview
8.3.2.2. mRNA Custom Synthesis Service Portfolio

8.3.3. Aurigene Pharmaceutical Services
8.3.3.1. Company Overview
8.3.3.2. mRNA Custom Synthesis Service Portfolio

9. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
9.1. mRNA Contract Manufacturing Service Providers: Market Landscape
9.1.1. Analysis by Year of Establishment
9.1.2. Analysis by Company Size
9.1.3. Analysis by Location of Headquarters (Region)
9.1.4. Analysis by Location of Headquarters (Country)
9.1.5. Analysis by Location of Manufacturing Facility
9.1.6. Analysis by Type of Additional Services
9.1.7. Analysis by Type of Product Manufactured
9.1.8. Analysis by Scale of Operation

10. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodology
10.3. Scoring Criteria

10.4. mRNA Contract Manufacturing Service Providers: Company Competitiveness Analysis
10.4.1. mRNA Contract Manufacturing Service Providers based in North America
10.4.2. mRNA Contract Manufacturing Service Providers based in Europe
10.4.3. mRNA Contract Manufacturing Service Providers based in Asia-Pacific

11. COMPANY PROFILES: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS
11.1. Chapter Overview
11.2. Detailed Company Profiles of Leading Service Providers
11.2.1. Eurogentac
11.2.1.1. Company Overview
11.2.1.2. mRNA Contract Manufacturing Services Portfolio
11.2.1.3. Recent Developments and Future Outlook

11.2.2. WuXi Biologics
11.2.2.1. Company Overview
11.2.2.2. mRNA Contract Manufacturing Services Portfolio
11.2.2.3. Recent Developments and Future Outlook

11.2.3. Merck
11.2.3.1. Company Overview
11.2.3.2. mRNA Contract Manufacturing Services Portfolio
11.2.3.3. Recent Developments and Future Outlook

11.3. Short Profiles of Other Prominent Service Providers
11.3.1. ST Pharm
11.3.1.1. Company Overview
11.3.1.2. mRNA Contract Manufacturing Services Portfolio

11.3.2. Vernal Biosciences
11.3.2.1. Company Overview
11.3.2.2. mRNA Contract Manufacturing Services Portfolio

11.3.3. Curia
11.3.3.1. Company Overview
11.3.3.2. mRNA Contract Manufacturing Services Portfolio

12. mRNA SYNTHESIS KIT PROVIDERS: MARKET LANDSCAPE
12.1. mRNA Synthesis Kits: Market Landscape
12.1.1. Analysis by Kit Components
12.1.2. Analysis by Type of Enzyme
12.1.3. Analysis by Type of Enzyme Mix Used
12.1.4. Analysis by mRNA Component Modified
12.1.5. Analysis by Number of Reaction
12.1.6. Analysis by Yield per Reaction
12.1.7. Analysis by Reaction Run-time
12.1.8. Analysis by Kit Price
12.1.9. Most Active Players: Analysis by Number of Kits Offered

12.2. mRNA Synthesis Kits: Providers Landscape
12.2.1. Analysis by Year of Establishment
12.2.2. Analysis by Company Size
12.2.3. Analysis by Location of Headquarters

13. mRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Scoring Criteria
13.4. mRNA Synthesis Kits: Product Competitiveness Analysis

14. COMPANY PROFILES: mRNA SYNTHESIS KIT PROVIDERS
14.1. Chapter Overview
14.2. Jena Biosciences
14.2.1. Company Overview
14.2.2. mRNA Synthesis Kits Portfolio

14.3. APExBIO
14.3.1. Company Overview
14.3.2. mRNA Synthesis Kits Portfolio

14.4. Thermo Fisher Scientific
14.4.1. Company Overview
14.4.2. mRNA Synthesis Kits Portfolio

14.5. CELLSCRIPT
14.5.1. Company Overview
14.5.2. mRNA Synthesis Kits Portfolio

14.6. New England Biolabs
14.6.1. Company Overview
14.6.2. mRNA Synthesis Kits Portfolio

14.7. Enzynomics
14.7.1. Company Overview
14.7.2. mRNA Synthesis Kits Portfolio

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Partnership Models
15.2. mRNA Synthesis and Manufacturing: Partnerships and Collaborations
15.1.1. Analysis by Year of Partnership
15.1.2. Analysis by Type of Partnership
15.1.3. Analysis by Year and Type of Partnership
15.1.4. Analysis by Type of Product
15.1.5. Analysis by Type of Partner
15.1.6. Most Active Players: Analysis by Number of Partnerships

15.1.7. Analysis by Geography
15.1.7.1. Intracontinental and Intercontinental Deals
15.1.7.2. Local and International Deals

16. LIKELY PARTNER ANALYSIS
16.1. Methodology and Key Parameters
16.2. Scoring Criteria
16.3. mRNA Drug Developers: Likely Partners based in North America
16.3.1. mRNA Drug Developers: Most Likely Partners based in North America

16.4. mRNA Drug Developers: Likely Partners based in Europe
16.4.1. mRNA Drug Developers: Most Likely Partners based in Europe

16.5. mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World
16.5.1. mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World

17. BIG PHARMA INITIATIVES
17.1. Analysis Methodology
17.2. Scoring Criteria
17.3. Big Pharma Players: mRNA- focused Initiatives
17.4. Competitive Benchmarking of Big Pharma Players

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges

19. GLOBAL mRNA SYNTHESIS AND MANUFACTURING MARKET
19.1. Chapter Overview
19.2. Key Assumptions and Forecast Methodology
19.3. Global mRNA Synthesis and Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
19.3.1. Scenario Analysis

19.4. Key Market Segmentations

20. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY TYPE OF PRODUCT
20.1. Chapter Overview
20.2. Key Assumptions and Forecast Methodology
20.3. mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2021, 2024 and 2035
20.3.1. mRNA Synthesis and Manufacturing: Market for Drug Substances (APIs), till 2035 (USD Billion)
20.3.2. mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), till 2035 (USD Billion)

21. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY APPLICATION AREA
21.1. Chapter Overview
21.2. Key Assumptions and Forecast Methodology
21.3. mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2021, 2024 and 2035
21.3.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, till 2035 (USD Billion)
21.3.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, till 2035 (USD Billion)

22. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY THERAPEUTIC AREA
22.1. Chapter Overview
22.2. Key Assumptions and Forecast Methodology
22.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2021, 2023 and 2035
22.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, till 2035 (USD Billion)
22.3.2. mRNA Synthesis and Manufacturing Market for Oncological Disorders, till 2035 (USD Billion)
22.3.3 mRNA Synthesis and Manufacturing Market for Other Disorders, till 2035 (USD Billion)

23. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
23.1. Chapter Overview
23.2. Key Assumptions and Forecast Methodology
23.3. mRNA Synthesis and Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2024 and 2035
23.3.1 mRNA Synthesis and Manufacturing Market in North America, till 2035 (USD Billion)
23.3.2. mRNA Synthesis and Manufacturing Market in Europe, till 2035 (USD Billion)
23.3.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
23.3.4. mRNA Synthesis and Manufacturing Market in Latin America, till 2035 (USD Billion)
23.3.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
23.3.6. mRNA Synthesis and Manufacturing Market in Rest of the World, till 2035, USD Billion

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Canvax
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Bernardo Jose Gómez Fernández, Business Development Manager

24.3. GC Pharma
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Jaehoon Moon, Team Leader

24.4 Tebubio
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Jean-François, Chief Commercial Officer

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

ページTOPに戻る

List of Tables/Graphs

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: mRNA Custom Synthesis Service Providers Market Landscape
Figure 4.2 Executive Summary: mRNA Contract Manufacturing Service Providers Market Landscape
Figure 4.3 Executive Summary: mRNA Synthesis Kits Market Landscape
Figure 4.4 Executive Summary: Partnership and Collaborations
Figure 4.5 Executive Summary: Big Pharma Initiatives
Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Structure of mRNA
Figure 5.2 Evolution of mRNA Vaccines
Figure 5.3 Steps involved in mRNA Synthesis
Figure 6.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
Figure 6.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
Figure 6.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
Figure 6.4 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered
Figure 6.5 mRNA Custom Synthesis Service Providers: Distribution by Starting Material
Figure 6.6 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
Figure 6.7 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method
Figure 6.8 mRNA Custom Synthesis Service Providers: Distribution by Application Area
Figure 6.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation
Figure 7.1 Company Competitiveness Analysis: mRNA Custom Synthesis Service Providers based in North America
Figure 7.2 Company Competitiveness Analysis: Benchmarking of mRNA Custom Synthesis Service Providers in North America
Figure 7.3 Company Competitiveness Analysis: mRNA Custom Synthesis Service Providers based in Europe
Figure 7.4 Company Competitiveness Analysis: Benchmarking of mRNA Custom Synthesis Service Providers in Europe
Figure 7.5 Company Competitiveness Analysis: mRNA Custom Synthesis Service Providers based in Asia-Pacific
Figure 7.6 Company Competitiveness Analysis: Benchmarking of mRNA Custom Synthesis Service Providers in Asia-Pacific
Figure 9.1 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
Figure 9.2 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
Figure 9.3 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Region)
Figure 9.4 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters (Country)
Figure 9.5 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Figure 9.6 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services
Figure 9.7 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured
Figure 9.8 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation
Figure 10.1 Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in North America
Figure 10.2 Company Competitiveness Analysis: Benchmarking of mRNA Contract Manufacturing Service Providers in North America
Figure 10.3 Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Europe
Figure 10.4 Company Competitiveness Analysis: Benchmarking of mRNA Contract Manufacturing Service Providers in Europe
Figure 10.5 Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Asia-Pacific
Figure 10.6 Company Competitiveness Analysis: Benchmarking of mRNA Contract Manufacturing Service Providers in Asia-Pacific
Figure 12.1 mRNA Synthesis Kits: Distribution by Kit Components
Figure 12.2 mRNA Synthesis Kits: Distribution by Type of Enzyme
Figure 12.3 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
Figure 12.4 mRNA Synthesis Kits: Distribution by mRNA Component Modified
Figure 12.5 mRNA Synthesis Kits: Distribution by Number of Reaction
Figure 12.6 mRNA Synthesis Kits: Distribution by Yield Per Reaction
Figure 12.7 mRNA Synthesis Kits: Distribution by Reaction Run-time
Figure 12.8 mRNA Synthesis Kits: Distribution by Kit Price
Figure 12.9 Most Active Players: Distribution by Number of Kits Offered
Figure 12.10 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
Figure 12.11 mRNA Synthesis Kit Providers: Distribution by Company Size
Figure 12.12 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
Figure 13.1 Product Competitiveness Analysis: mRNA Synthesis Kits
Figure 15.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Type of Product (Broad)
Figure 15.5 Partnerships and Collaborations: Distribution by Type of Product (Specific)
Figure 15.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 15.7 Most Active Players: Distribution by Number of Partnerships
Figure 15.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 15.9 Partnerships and Collaborations: Local and International Deals
Figure 16.1 mRNA Drug Developers: Likely Partners based in North America
Figure 16.2 mRNA Drug Developers: Most Likely Partners based in North America
Figure 16.3 mRNA Drug Developers: Likely Partners based in Europe
Figure 16.4 mRNA Drug Developers: Most Likely Partners based in Europe
Figure 16.5 mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World
Figure 16.6 mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World
Figure 17.1 Benchmarking of Big Pharma Players: Spider Web Analysis
Figure 17.2 Big Pharma Players: Distribution by Portfolio Diversity
Figure 17.3 Big Pharma Players: Distribution by Therapeutic Diversity
Figure 17.4 Big Pharma Players: Distribution by Number of Initiatives
Figure 18.1. Market Trends and Outlook: Key Growth Drivers
Figure 18.2. Market Trends and Outlook: Market Restraints
Figure 18.3. Market Trends and Outlook: Opportunities
Figure 18.4. Market Trends and Outlook: Challenges
Figure 19.1 Global mRNA Synthesis and Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
Figure 20.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2021, 2024 and 2035
Figure 20.2 mRNA Synthesis and Manufacturing: Market for Drug Substances (APIs), till 2035
Figure 20.3 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), till 2035
Figure 21.1 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2021, 2024 and 2035
Figure 21.2 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, till 2035
Figure 21.3 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, till 2035
Figure 22.1 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2021, 2024 and 2035
Figure 22.2 mRNA Synthesis and Manufacturing Market for Infectious Diseases, till 2035
Figure 22.3 mRNA Synthesis and Manufacturing Market for Oncological Disorders, till 2035
Figure 22.4 mRNA Synthesis and Manufacturing Market for Other Disorders, till 2035
Figure 23.1 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2021, 2024 and 2035
Figure 23.2 mRNA Synthesis and Manufacturing Market in North America, till 2035
Figure 23.3 mRNA Synthesis and Manufacturing Market in Europe, till 2035
Figure 23.4 mRNA Synthesis and Manufacturing Market in Asia-Pacific, till 2035
Figure 23.5 mRNA Synthesis and Manufacturing Market in Rest of the World, till 2035